7-Bromo-4-chloroquinazoline: Handling & Synthesis Protocol

7-bromo-4-chloroquinazoline is a bifunctional halogenated heterocyclic building block widely employed in medicinal chemistry for the synthesis of kinase inhibitors and other pharmacologically active quinazoline derivatives via selective nucleophilic substitution at C-4 and palladium-catalyzed cross-coupling at C-7.

CAS Number

876343-37-2

Molecular Formula

C₈H₄BrClN₂

Molecular Weight

243.49 g/mol

Reactive Sites

C-4 chloro (electrophilic, SNAr); C-7 bromo (oxidative addition, cross-coupling)

Recommended Storage

Sealed, dry, cool conditions away from light and moisture

Primary Application

Intermediate for kinase inhibitor and quinazoline-based drug synthesis

SKU

B176828

Overview and Chemical Properties

7-Bromo-4-chloroquinazoline (SKU B176828) is a dihalogenated bicyclic heterocycle featuring a quinazoline core substituted with a chlorine atom at the 4-position and a bromine atom at the 7-position. The electron-deficient aromatic ring system makes the C-4 chloro substituent highly susceptible to nucleophilic aromatic substitution (SNAr), while the C-7 bromo substituent serves as an excellent handle for palladium-catalyzed cross-coupling reactions such as Suzuki–Miyaura, Buchwald–Hartwig, and Sonogashira couplings.

This orthogonal reactivity allows medicinal chemists to introduce two distinct chemical fragments in a controlled, sequential manner, making 7-bromo-4-chloroquinazoline one of the most versatile quinazoline scaffolds available for drug discovery programs, particularly in the development of EGFR, HER2, and other receptor tyrosine kinase inhibitors.

Safety and Handling Precautions

Before working with 7-bromo-4-chloroquinazoline, consult the Safety Data Sheet (SDS). The compound should be handled in a well-ventilated fume hood. Appropriate personal protective equipment (PPE) including chemical-resistant gloves, laboratory coat, and safety goggles must be worn at all times.

Store the reagent in a tightly sealed container under dry, cool, and dark conditions. Prolonged exposure to moisture or elevated temperatures may lead to hydrolysis or decomposition. Avoid inhalation of dust or aerosols. In case of skin or eye contact, flush immediately with copious water and seek medical attention. Dispose of waste material in accordance with local regulations governing halogenated organic compounds.

Protocol: Selective Nucleophilic Substitution at C-4

Objective: To introduce an amine or thiol nucleophile selectively at the C-4 position of 7-bromo-4-chloroquinazoline while preserving the C-7 bromo group for subsequent cross-coupling.

Materials:

• 7-Bromo-4-chloroquinazoline (B176828, 1.0 equiv)
• Primary or secondary amine nucleophile (1.0–1.2 equiv)
• Solvent: anhydrous isopropanol (IPA), THF, or DMF
• Base (optional): N,N-diisopropylethylamine (DIPEA, 1.5–2.0 equiv) to scavenge HCl generated
• Inert atmosphere (N₂ or Ar)

Procedure:

1. Charge a round-bottom flask with 7-bromo-4-chloroquinazoline and dissolve in the chosen solvent (0.1–0.5 M).
2. Add the amine nucleophile (1.0–1.2 equiv) and DIPEA (1.5 equiv) if required.
3. Stir the reaction at room temperature to 60 °C for 1–12 hours, monitoring by TLC or LC-MS.
4. Upon completion, concentrate the mixture under reduced pressure.
5. Purify the product by column chromatography (silica gel, ethyl acetate/hexane gradient) or recrystallization.
6. Confirm product identity by ¹H NMR, ¹³C NMR, and HRMS. The C-7 bromo substituent is retained for downstream functionalization.

Note: Reaction temperature and solvent choice should be optimized for each specific nucleophile. More hindered amines may require elevated temperatures or longer reaction times.

Protocol: Palladium-Catalyzed Cross-Coupling at C-7

Objective: To perform a Suzuki–Miyaura cross-coupling reaction at the C-7 bromo position following SNAr functionalization at C-4, enabling diversification of the quinazoline scaffold.

Materials:

• C-4 functionalized 7-bromoquinazoline intermediate (1.0 equiv)
• Aryl or heteroaryl boronic acid (1.2–1.5 equiv)
• Pd catalyst: Pd(PPh₃)₄ or Pd(dppf)Cl₂ (2–5 mol%)
• Base: K₂CO₃ or Cs₂CO₃ (2.0–3.0 equiv)
• Solvent: 4:1 dioxane/water or DMF/water
• Inert atmosphere (N₂ or Ar)

Procedure:

1. In a microwave vial or Schlenk flask, combine the bromoquinazoline intermediate, boronic acid, Pd catalyst, and base.
2. Add degassed solvent and seal the vessel.
3. Heat to 80–100 °C for 2–16 hours (conventional heating) or 120–140 °C for 15–30 minutes (microwave).
4. Cool to room temperature and filter through Celite to remove palladium residues.
5. Extract with ethyl acetate, wash with brine, dry over MgSO₄, and concentrate.
6. Purify by column chromatography and confirm structure by NMR and HRMS.

Note: Palladium catalyst loading, ligand choice, and base should be optimized for each substrate combination. The presence of nitrogen atoms in the quinazoline ring may coordinate to palladium; bulky phosphine ligands can mitigate catalyst poisoning.

Troubleshooting and Yield Optimization

Low conversion in SNAr: Increase reaction temperature gradually (up to 80 °C) or switch to a more polar aprotic solvent such as DMF. Ensure the nucleophile is sufficiently nucleophilic; free-base form of amines is preferred over hydrochloride salts. Adding excess base (DIPEA or TEA) can improve conversion.

Undesired disubstitution: Carefully control nucleophile equivalents (≤1.2 equiv) and monitor reaction progress by TLC or LC-MS. Reduce reaction temperature and time to minimize over-reaction at C-7.

Poor cross-coupling yield: Ensure rigorous exclusion of oxygen and moisture by thoroughly degassing all solvents and reagents. Increase Pd catalyst loading to 5 mol% if conversion is incomplete. Screen alternative ligands (e.g., SPhos, XPhos) to enhance catalyst stability with nitrogen-rich substrates. If palladium black formation is observed, reduce temperature or switch to a more active precatalyst system.

Product purification difficulties: Consider switching from silica gel chromatography to reverse-phase HPLC for polar quinazoline products. Recrystallization from ethanol/water mixtures can also provide high-purity material.

Frequently asked questions

What is the preferred order of functionalization for 7-bromo-4-chloroquinazoline?

The recommended sequence is to perform SNAr substitution at C-4 first, reacting the chloro group with the desired amine or other nucleophile under mild conditions. The C-7 bromo group is then used in a palladium-catalyzed cross-coupling reaction in a subsequent step. This order takes advantage of the greater electrophilicity of C-4 and preserves the bromo handle for metal-catalyzed chemistry.

Can 7-bromo-4-chloroquinazoline be used directly in cross-coupling reactions at C-7 without prior C-4 modification?

Yes, Suzuki–Miyaura or other palladium-catalyzed cross-couplings can be carried out at C-7 directly on the intact compound. However, care must be taken to avoid unintended nucleophilic attack at C-4 under the basic aqueous conditions typically used in coupling reactions. Optimizing base strength and reaction temperature is advisable when working with the unprotected C-4 chloro substrate.

What solvents and bases are most compatible with SNAr reactions on this substrate?

Anhydrous isopropanol, THF, and DMF are commonly employed solvents. Isopropanol is particularly convenient as it dissolves the substrate well and facilitates product isolation. For base, DIPEA or triethylamine (TEA) are effective at scavenging the HCl by-product without competing with the nucleophile. Water should be minimized to prevent hydrolysis of the chloro group.

How should 7-bromo-4-chloroquinazoline be stored to maintain stability?

The compound should be stored in a tightly sealed container under dry, cool, and dark conditions. Moisture can promote hydrolysis of the C-4 chloro group over time. It is advisable to store the reagent with a desiccant and to minimize repeated opening of the container by aliquoting the material if multiple uses are anticipated.

Is 7-bromo-4-chloroquinazoline relevant to EGFR inhibitor synthesis?

The quinazoline scaffold is a privileged structure in kinase inhibitor drug discovery, and many EGFR-targeting agents are built on 4-aminoquinazoline frameworks. 7-Bromo-4-chloroquinazoline provides a versatile starting point for introducing aniline-type substituents at C-4 and aryl or heteroaryl groups at C-7, enabling the construction of EGFR inhibitor analogues. Specific applications should be confirmed against the primary literature.

References

1. Rewcastle, G. W. et al. Tyrosine kinase inhibitors. 5. Synthesis and structure-activity relationships for 4-[(phenylmethyl)amino]- and 4-(phenylamino)quinazolines as potent adenosine 5'-triphosphate binding site inhibitors of the tyrosine kinase domain of the epidermal growth factor receptor. Journal of Medicinal Chemistry, 1995.
2. Miyaura, N.; Suzuki, A. Palladium-Catalyzed Cross-Coupling Reactions of Organoboron Compounds. Chemical Reviews, 1995, 95(7), 2457–2483. doi:10.1021/cr00039a007
3. Clayden, J.; Greeves, N.; Warren, S. Organic Chemistry, 2nd ed. Oxford University Press, 2012. Chapter on nucleophilic aromatic substitution.

Products are supplied for research and development use only. Not for use in humans, animals, diagnosis, or therapy.